Lexicon Pharmaceuticals, Inc.
NASDAQ Global SelectTotal Valuation
Lexicon Pharmaceuticals, Inc. carries a market capitalization of 995.00M, placing it among publicly traded companies globally. Its enterprise value stands at 936.52M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 995.00M |
| Enterprise Value | 936.52M |
Share Statistics
Lexicon Pharmaceuticals, Inc. currently has 444.94M shares outstanding.
| Shares Outstanding | 444.94M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 22.64, and the price-to-book ratio stands at 6.12.
| PE Ratio | N/A |
| PS Ratio | 22.64 |
| PB Ratio | 6.12 |
| P/TBV Ratio | 8.22 |
| P/FCF Ratio | -14.45 |
| P/OCF Ratio | -14.45 |
Enterprise Valuation
| EV / Sales | 22.58 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Lexicon Pharmaceuticals, Inc. maintains a current ratio of 13.37, meaning it holds 13.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 33.97, indicating elevated leverage, while an interest coverage ratio of -6.44 demonstrates limited ability to service its debt obligations.
| Current Ratio | 13.37 |
| Quick Ratio | 13.07 |
| Debt / Equity | 33.97 |
| Debt / EBITDA | -1.10 |
| Interest Coverage | -6.44 |
Financial Efficiency
| Return on Equity (ROE) | -40.21 |
| Return on Assets (ROA) | -25.70 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.52 |
Stock Price Statistics
Lexicon Pharmaceuticals, Inc.'s stock has gained approximately 105.50459% over the past 52 weeks. The 50-day moving average sits at 2.32, while the 200-day moving average is 1.79.
| Beta (5Y) | N/A |
| 52-Week Price Change | 105.50459% |
| 50-Day Moving Average | 2.32 |
| 200-Day Moving Average | 1.79 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Lexicon Pharmaceuticals, Inc. generated 41.47M in revenue and converted that into -61.12M in net income, yielding earnings per share of -0.16. EBITDA reached -54.02M, while operating income came in at -54.50M.
| Revenue | 41.47M |
| Gross Profit | 41.11M |
| Operating Income | -54.50M |
| Pretax Income | -61.12M |
| Net Income | -61.12M |
| EBITDA | -54.02M |
| EBIT | -54.50M |
| Earnings Per Share (EPS) | -0.16 |
Balance Sheet
Lexicon Pharmaceuticals, Inc. holds 190.61M in cash and equivalents against 59.28M in total debt, resulting in a net debt position of 10.51M. Total book value stands at 174.53M, with working capital of 181.87M providing operational flexibility.
| Cash & Cash Equivalents | 190.61M |
| Total Debt | 59.28M |
| Net Debt | 10.51M |
| Equity (Book Value) | 174.53M |
| Book Value Per Share | 0.39 |
| Working Capital | 181.87M |
Cash Flow
Lexicon Pharmaceuticals, Inc. produced -64.99M in operating cash flow over the past twelve months.
| Operating Cash Flow | -64.99M |
| Capital Expenditures | N/A |
| Free Cash Flow | -64.99M |
| FCF Per Share | -0.17 |
Margins
Lexicon Pharmaceuticals, Inc. operates with a gross margin of 99.14, reflecting its pricing power and cost economics. The operating margin of -131.43 and net profit margin of -147.38 provide insight into operational efficiency.
| Gross Margin | 99.14 |
| Operating Margin | -131.43 |
| Pretax Margin | -147.38 |
| Profit Margin | -147.38 |
| EBITDA Margin | -130.27 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -7.99 |
| FCF Yield | -6.92 |
Stock Splits
Lexicon Pharmaceuticals, Inc.'s most recent stock split took place on May 21, 2015 with a 7:1 split ratio.
| Last Split Date | 5/21/2015 |
| Split Ratio | 7:1 |
Scores
Lexicon Pharmaceuticals, Inc. posts an Altman Z-Score of -5.10, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -5.10 |